385920 HSP90 Inhibitor, CCT018159 - CAS 171009-07-7 - Calbiochem

385920
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₂₀H₂₀N₂O₄ 171009-07-7

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      385920-5MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 5 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable pyrazoloresorcinol compound that inhibits HSP90 ATPase activity (IC50 = 3.2 µM and 6.6 µM against human HSP90β and yeast HSP90, respectively) by targeting the enzyme's N-terminal ATP binding site. It exhibits no detectable effects against human Hsp70 or topoisomerase II even at concentrations as high as 100 µM and inhibits a panel of 20 commonly studied kinases only at much higher concentrations. Unlike 17-AAG (Cat. No. 100068), the antitumor activity of CCT018159 is not affected by the expression of NQ01/DT-diaphorase or P-glycoprotein.
          Catalogue Number385920
          Brand Family Calbiochem®
          Synonyms4-(4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl)-6-ethylresorcinol
          References
          ReferencesHardcastle, A., et al. 2007. Mol. Cancer Ther. 6, 1112.
          Sharp, S.Y., et al. 2007. Cancer Res. 67, 2206.
          Smith, N.F., et al. 2006. Mol. Cancer Ther. 5, 1628.
          Dymock, B.W., et al. 2005. J. Med. Chem. 48, 4212.
          Cheung, K.M., et al. 2005. Bioorg. Med. Chem. Lett. 15, 3338.
          Product Information
          CAS number171009-07-7
          FormWhite solid
          Hill FormulaC₂₀H₂₀N₂O₄
          Chemical formulaC₂₀H₂₀N₂O₄
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Purity≥98% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 36/37/38

          Irritating to eyes, respiratory system and skin.
          S PhraseS: 24/25-36/37/39

          Avoid contact with skin and eyes.
          Wear suitable protective clothing, gloves and eye/face protection.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Irritant
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solution are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          385920

          References

          Reference overview
          Hardcastle, A., et al. 2007. Mol. Cancer Ther. 6, 1112.
          Sharp, S.Y., et al. 2007. Cancer Res. 67, 2206.
          Smith, N.F., et al. 2006. Mol. Cancer Ther. 5, 1628.
          Dymock, B.W., et al. 2005. J. Med. Chem. 48, 4212.
          Cheung, K.M., et al. 2005. Bioorg. Med. Chem. Lett. 15, 3338.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision06-March-2008 JSW
          Synonyms4-(4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl)-6-ethylresorcinol
          DescriptionA cell-permeable pyrazoloresorcinol compound that inhibits HSP90 ATPase activity (IC50 = 3.2 µM and 6.6 µM against human HSP90β and yeast HSP90, respectively) by targeting the enzyme's N-terminal ATP binding site. It exhibits no detectable effects against human Hsp70 or topoisomerase II even at concentrations as high as 100 µM and inhibits a panel of 20 commonly studied kinases only at much higher concentrations. Unlike 17-AAG (Cat. No. 100068), the antitumor activity of CCT018159 is not affected by the expression of NQ01/DT-diaphorase or P-glycoprotein.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number171009-07-7
          Chemical formulaC₂₀H₂₀N₂O₄
          Structure formulaStructure formula
          Purity≥98% by HPLC
          SolubilityDMSO (35 mg/ml), H₂O (1.7 mg/ml) or Ethanol (35 mg/ml)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solution are stable for up to 3 months at -20°C.
          Toxicity Irritant
          ReferencesHardcastle, A., et al. 2007. Mol. Cancer Ther. 6, 1112.
          Sharp, S.Y., et al. 2007. Cancer Res. 67, 2206.
          Smith, N.F., et al. 2006. Mol. Cancer Ther. 5, 1628.
          Dymock, B.W., et al. 2005. J. Med. Chem. 48, 4212.
          Cheung, K.M., et al. 2005. Bioorg. Med. Chem. Lett. 15, 3338.